Why the study?
Does prolonged β-blocker use beyond 3 years post-MI improve long-term outcomes in elderly patients?
Does prolonged β-blocker use beyond 3 years post-MI improve long-term outcomes in elderly patients?
Prolonged beta-blocker therapy beyond 3 years post-MI in older adults does not appear to provide additional prognostic benefit.
Answers are grounded in this paper and cite their sources.
May not support indefinite β-blocker use beyond 3 years post-MI in older adults; leaves open whether RCTs would alter current recommendations.
In this observational analysis, β-blocker use beyond 3 years post-MI, regardless of the dose achieved, was not associated with improved outcomes. The role of prolonged β-blocker use, particularly in older adults, needs further investigation.
No takes yet. Share an insight, caveat, or question.
Shavadia et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: